MasTec Short Sellers Ease Up, But Analysts Keep Cutting
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
MasTec enters its October 29 earnings release with short sellers having trimmed their position meaningfully over the past month, even as the stock has suffered one of its steepest declines of the year.
Short interest now stands at 5.9% of the free float, down 11% from a month ago. The reduction is concentrated around early October: positions ran above 5.6 million shares through late September and the first week of October, then dropped sharply to around 4.6 million and have held near that level since. The borrow market reflects no particular stress. Availability is extremely loose at 1,844%, meaning there are roughly 18 shares available to lend for every one already borrowed. Cost to borrow has ticked up 13% over the past week to 0.45%, but that figure remains low in absolute terms and well within the range of the past 30 days.
What has moved more dramatically is the stock itself. MTZ closed at $171.05 on October 23, down 10.5% on the week and 23% over the past month. The peer group offers little comfort: closest correlated names including MYRG, PWR, and DY fell 9%, 14%, and 11% respectively over the week, suggesting the sector is under broad pressure. FIX fared worst among peers, dropping 19% on the week. Options positioning has edged more defensive into the print, with the put/call ratio now at 0.795, about 1.9 standard deviations above its 20-day average of 0.64. That is notably more cautious than the reading published in ORTEX's prior article on October 20, when the ratio was at 0.77 on a z-score near 3.9 against the then-prevailing mean. The z-score has moderated since, though the ratio itself has drifted higher.
Analyst activity has been relentless on the downside. Citigroup cut its target to $308 from $408 on October 23, the most recent in a string of reductions that also included JP Morgan, Barclays, Keybanc, Stifel, and TD Cowen over the past three weeks. Every firm kept a buy-equivalent rating. The mean consensus target now sits around $360, more than double the current price, a gap that reflects the market's scepticism rather than Street conviction. The bull case rests on a $21 billion backlog, book-to-bill above 1.2x, and management's own guidance for more than $15 billion in revenue and $8 of EPS in 2026. The bear case is that the Communications segment, the largest by revenue, saw its guidance cut to roughly $3.25 billion with EBITDA margins reset to high single digits, and that fixed-price work, labor scarcity, and policy-dependent end markets leave earnings quality fragile regardless of backlog coverage.
Two 13D filers sit on the activist register. Jorge Mas holds 14.8% of the class and Jose Ramon Mas holds 7.7%, both last disclosed in August 2026. Stakes are as-last-disclosed and positions can fall below 5% without a further filing. On the institutional side, BlackRock added 584,000 shares as of September 30, and JP Morgan Asset Management added over 1.1 million shares in the same period, suggesting some large institutions were buying into the weakness even as the stock was selling off.
The print will test whether management's confidence in Power Delivery and clean energy work is enough to absorb the Communications shortfall, and whether the margin recovery story that underpinned a $508 Goldman Sachs target just three months ago still has a credible timeline.
Stocks in this article
See the live data behind this article on ORTEX.
Open MTZ on ORTEX →How this article was generated
- Generated
- 26 Oct 2026, 04:13
- Data as of
- 26 Oct 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.